© 2010 Profil Institut für Stoffwechselforschung GmbH • Hellersberggstrasse 9 • 41460 Neuss • Germany

Congress News

Profil contributes to the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, September 21-24, 2010

Oral Presentations

  • A novel pH-neutral formulation of the monomeric insulin VIAject® has a faster onset of action than insulin lispro
    Nosek L, Heise T, Flacke F, Krasner A, Pichotta P, Heinemann L, Steiner S

  • Accuracy of a continuous glucose monitoring System (CGMS): still room for improvement
    Heckermann S, Nosek L, Zijlstra E, Heise T

  • Intensive care unit (ICU) glucose monitoring measured in plasma using mid-infrared spectroscopy
    Lim G, Calentine C, Gable J, Nosek L, Heise T

Posters

  • Linagliptin, a novel DPPIV inhibitor: no need for dose adjustment in patients with renal impairment
    Graefe-Mody U, Friedrich C, Port A, Ring A, Heise T, Halabi A, Woerle HJ

  • Restoration of insulin release with lixisenatide in patients with type 2 diabetes
    Becker RH, Ruus P, Liu YH, Kapitza C

  • Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes: results of a phase 1b study
    Rothenberg PL, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Blake J, Wexler D, Tan Y, Smulders K, Demarest K, Sha S

  • Insulin degludec: less pharmaocodynamic variability than insulin glargine under steady state conditions
    Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, Haahr H


Profil contributed to the American Diabetes Association´s 70th Scientific Sessions in Orlando, FL, June 25-29, 2010

Oral Presentations

  • Once-Daily Use of a New Generation Ultra-Long Acting Basal Insulin with a Bolus Boost in Insulin-Naïve Subjects with Type 2 Diabetes: Comparison with Insulin Glargine
    Heise T, Tack C, Cuddihy RM, Davidson J, Gouet D, Liebl A, Bobillo ER, Mersebach H, Dykiel P, Jorde R

  • Intensive Care Unit (ICU) Glucose Monitoring Measured in Plasma Using Mid-Infrared Spectroscopy
    Heise T, Nosek L, Lim G, Calentine C

  • Accuracy of a Novel Continuous Glucose Monitoring System (CGMS) Using Intravenous (iv) Microdialysis
    Zijlstra E, Hartlep M, O´Connell M, Heise T, Künnecke W

Posters

  • A Novel pH-Neutral Formulation of the Monomeric Insulin VIAject® Has a Faster Onset of Action Than Insulin Lispro
    Heise T, Nosek L, Flacke F, Krasner A, Pichotta P, Heinemann L, Steiner S

  • Accuracy of a Continuous Glucose Monitoring System (CGMS): Still Room for Improvement
    Heckermann S, Nosek L, Zijlstra E, Heise T

  • Restoration of Insulin Release with Lixisenatide in Patients with Type 2 Diabetes
    Becker RHA, Ruus P, Steinstraesser A, Kapitza C

  • Phase I study of Taspoglutide Immediate Release Formulation (IRF) on Insulin Secretion in Patients (pts) with Type 2 Diabetes (T2D)
    Pellenda C, Mangold B, Schulte M, Niggli M, Kapitza C

  • KB003305, a Liver-Targeted Glucocorticoid Receptor Antagonist: A First-In-Man Study To Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses in Healthy Male Volunteers
    Kapitza C, Jax T, Nilsson S, Breuer O

  • The Effect of KB003305, a Liver-Targeted Glucocorticoid Receptor Antagonist, on Fasting Plasma Glucose and Oral Glucose Tolerance after Multiple Oral Doses in Patients with Diabetes Type 2
    Jax T, Kapitza C, Nilsson S, Breuer O

  • Impact of Atorvastatin Treatment on Residual Beta Cell Function in Recent-Onset Type 1 Diabetes
    Kolb H, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Martin S

  • BI 10773, a Sodium-Glucose Co-Transporter Inhibitor (SGLT-2), Is Safe and Efficacious Following 4-Week Treatment in Patients with Type 2
    Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, Seman L, Woerle HJ

  • Safety and Tolerability of BI 10773, a Sodium-Glucose Co-Transporter (SGLT-2) Inhibitor following 8-days Treatment in Patients with Type 2 Diabetes
    Seman L, Macha S, Jones P, Marquart A, Port A, Pinnetti S, Heise T, Dugi KA

  • Characterization of Metabolism Parameters Following Technosphere® Insulin and Insulin Lispro
    Potocka E, Hovorka R, Baughman R, Klein O, Dellweg S,Umpleby M, Haworth P, Mills R, Boss AH, Richardson PC

  • Canagliflozin, a Novel Inhibitor of Sodium Glucose Co-transporter 2, Improved Glucose Control in Subjects with Type 2 Diabetes and Was Well Tolerated
    Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Blake J, Wexler D, Tan Y, Smulders K, Demarest K, Rothenberg P